The clinical problem the team set out to address is deceptively simple to state and notoriously hard to quantify. Diabetic neuropathy damages peripheral nerves through chronic exposure to high blood glucose, producing symptoms that range from burning pain and tingling in the feet to numbness, muscle weakness, and loss of balance. Because the damage is often insidious, patients may adapt their lives around it, walking less, sleeping poorly, withdrawing from social activity, and quietly losing vitality. Generic quality-of-life instruments can miss these specific burdens, while existing neuropathy-specific scales are lengthy, linguistically awkward, or validated only in Western populations. In Indonesia, where diabetes prevalence continues to climb and health systems face resource constraints, the absence of a validated, locally appropriate instrument has left clinicians and researchers without a practical yardstick.

The DN-SF11 was constructed in two deliberate stages. First, the authors conducted a structured literature review to identify the domains of life most consistently disrupted by diabetic neuropathy, then distilled them into eleven items spanning five dimensions: Pain, Physical Function, Therapy Impact, Vitality, and Mental Health. The choice of domains reflects a biopsychosocial model of the disease, in which nerve damage initiates a cascade that runs from physical symptoms through functional limitation to emotional consequences. Second, the draft items were scrutinized by experts using the Delphi method, an iterative consensus technique in which panelists rate and re-rate each item across successive rounds until agreement stabilizes. Each item was then scored with the Content Validity Index, a metric expressing the proportion of experts who judge an item relevant and clear, ensuring that every question earned its place on the form.

With the instrument drafted, the team moved to statistical validation in a pilot sample of 40 patients with diabetic neuropathy. Forty participants is a small cohort by the standards of psychometric research, and the authors are explicit that this is a preliminary study, but the sample size is defensible for exploratory work when paired with the right analytical machinery. That machinery was Partial Least Squares Structural Equation Modelling, or PLS-SEM, a variance-based approach that estimates relationships between latent constructs, the unobservable qualities such as pain or vitality that questionnaires attempt to measure through multiple indicators. Unlike covariance-based SEM, which typically requires several hundred respondents to estimate models reliably, PLS-SEM is designed for exactly the kind of small-sample, theory-building exercise this pilot represents.

The internal consistency results were the study’s clearest headline. Cronbach’s alpha, the standard statistic for how coherently a set of items measures a single construct, came out at 0.883 for the full instrument, comfortably above the conventional 0.70 threshold and approaching the 0.90 level often cited as excellent. In practical terms, this means the eleven items behave as if they are all probing the same underlying phenomenon of neuropathy-related quality of life, rather than measuring eleven loosely related things. For an instrument intended to be short enough for routine clinical use, achieving this level of coherence with so few items is the central technical achievement of the study.

Convergent and discriminant validity, the twin pillars of construct validation, also performed satisfactorily. Convergent validity asks whether items intended to measure the same dimension actually correlate strongly with one another, typically assessed through indicator loadings and average variance extracted. Discriminant validity asks the opposite question: whether dimensions that are conceptually distinct, such as Pain and Mental Health, can be statistically told apart rather than collapsing into one undifferentiated blob of distress. The DN-SF11 passed both tests, suggesting its five-dimension architecture is not merely a theoretical convenience but a structure that emerges from patients’ own responses. This matters because dimension-level scores are only meaningful if the dimensions genuinely differ.

Perhaps the most scientifically interesting findings came from the structural model, which maps hypothesized causal pathways among the dimensions. The analysis indicated that Physical Function and Therapy Impact both exert positive influences on Vitality, and that Vitality in turn significantly predicts Mental Health outcomes. Read as a pathway, the model suggests that how well patients can move and function, and how they experience the effects of their treatment, feed into their sense of energy and liveliness, which then shapes their psychological state. This chain, from body to spirit, echoes a well-established literature on the downstream mental health burden of chronic physical illness, but seeing it reproduced in an Indonesian neuropathy cohort with a purpose-built instrument gives the pathway local empirical grounding.

The therapeutic dimension deserves particular attention because it is often neglected in quality-of-life instruments. Patients with diabetic neuropathy are typically managed with analgesics, anticonvulsants, antidepressants repurposed for nerve pain, and strict glycemic control, and the side effects and daily burdens of these regimens can themselves degrade wellbeing. By including Therapy Impact as an explicit dimension, the DN-SF11 acknowledges that treatment is not a neutral backdrop but an active ingredient in the patient’s experienced quality of life. For clinical pharmacists, who are increasingly embedded in Indonesian diabetes care teams, a score that captures this dimension could flag patients whose regimens are technically effective yet subjectively corrosive.

The study’s limitations are acknowledged by its authors and are worth stating plainly. Forty participants cannot establish the stability of the instrument over time, since test-retest reliability requires repeated administration in a larger sample. Criterion validity against established gold-standard instruments, responsiveness to clinical change, and cross-regional generalizability across Indonesia’s linguistically and culturally diverse provinces all remain to be demonstrated. The authors themselves recommend further large-scale validation studies, and the PLS-SEM framework, while appropriate for exploration, produces estimates that should be treated as provisional until confirmed in bigger cohorts with more conservative modeling. The ethics approval from RSUD dr. H. Jusuf SK in North Kalimantan, conducted under the Declaration of Helsinki with written informed consent from all participants, does however establish a sound procedural foundation for that follow-up work.

Even so, the significance of a validated eleven-item scale should not be underestimated. Long questionnaires impose a real cost in busy outpatient clinics, and respondent fatigue degrades data quality in exactly the populations, elderly, painful, fatigued, where measurement matters most. A short form that preserves psychometric integrity opens the door to routine quality-of-life monitoring in Indonesian diabetes care, to locally grounded clinical trials of neuropathy therapies, and to health-economic analyses that can finally quantify the societal burden of diabetic nerve damage in the country. If subsequent large-scale validation confirms what this pilot suggests, the DN-SF11 could become a small questionnaire with an outsized role in how Indonesia measures, and ultimately improves, the lives of millions of patients living with diabetic neuropathy.

Subject of Research: Development and preliminary validation of a short quality-of-life questionnaire for diabetic neuropathy patients in Indonesia

Article Title: A pilot study on the development and preliminary validation of the diabetic neuropathy short form 11 to assess quality of life in Indonesia

Article References: Syuhada, S., Anggadiredja, K., Kurniati, N. F., & Akrom, A. (2026). A pilot study on the development and preliminary validation of the diabetic neuropathy short form 11 to assess quality of life in Indonesia. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00438-y

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00438-y

Keywords: diabetic neuropathy, quality of life, questionnaire validation, DN-SF11, PLS-SEM, Cronbach's alpha, Indonesia, psychometrics, mental health, chronic pain, Delphi method, pilot study